These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8420143

  • 1. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia.
    Dexter DT, Sian J, Jenner P, Marsden CD.
    Adv Neurol; 1993; 60():273-81. PubMed ID: 8420143
    [No Abstract] [Full Text] [Related]

  • 2. Functional neuroanatomy of the basal ganglia in Parkinson's disease.
    Wichmann T, DeLong MR.
    Adv Neurol; 2003; 91():9-18. PubMed ID: 12442660
    [No Abstract] [Full Text] [Related]

  • 3. Parkinson's disease is a neuropsychiatric disorder.
    Agid Y, Arnulf I, Bejjani P, Bloch F, Bonnet AM, Damier P, Dubois B, François C, Houeto JL, Iacono D, Karachi C, Mesnage V, Messouak O, Vidailhet M, Welter ML, Yelnik J.
    Adv Neurol; 2003; 91():365-70. PubMed ID: 12442695
    [No Abstract] [Full Text] [Related]

  • 4. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.
    Whitehouse PJ.
    Adv Neurol; 1987; 45():393-7. PubMed ID: 2881448
    [No Abstract] [Full Text] [Related]

  • 5. Clinical and pathological features of corticobasal degeneration.
    Gibb WR, Luthert PJ, Marsden CD.
    Adv Neurol; 1990; 53():51-4. PubMed ID: 2239491
    [No Abstract] [Full Text] [Related]

  • 6. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
    Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH.
    Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
    [Abstract] [Full Text] [Related]

  • 7. Iron and ferritin in substantia nigra in Parkinson's disease.
    Jellinger KA, Kienzl E, Rumpelmaier G, Paulus W, Riederer P, Stachelberger H, Youdim MB, Ben-Shachar D.
    Adv Neurol; 1993 Dec; 60():267-72. PubMed ID: 8420142
    [No Abstract] [Full Text] [Related]

  • 8. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E.
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [Abstract] [Full Text] [Related]

  • 9. [Quantitative studies of neurons of the substantia nigra and basal ganglia in parkinsonism].
    Togi H, Ogawa M, Yamanouchi H, Tomonaga M, Kameyama M.
    Rinsho Shinkeigaku; 1976 Apr; 16(4):311-8. PubMed ID: 986268
    [No Abstract] [Full Text] [Related]

  • 10. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA, Fox SH, Crossman AR, Brotchie JM.
    Adv Neurol; 2003 Apr; 91():273-91. PubMed ID: 12442686
    [No Abstract] [Full Text] [Related]

  • 11. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD.
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [Abstract] [Full Text] [Related]

  • 12. Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease.
    Watson DL, Carpenter CL, Marks SS, Greenberg DA.
    Ann Neurol; 1988 Mar; 23(3):303-5. PubMed ID: 2967667
    [Abstract] [Full Text] [Related]

  • 13. [Hallervorden-Spatz disease with Lewy bodies].
    Antoine JC, Tommasi M, Chalumeau A, Jouvet-Telinge A, Bourrat C.
    Rev Neurol (Paris); 1985 Mar; 141(12):806-9. PubMed ID: 3008295
    [Abstract] [Full Text] [Related]

  • 14. Iron metabolism and Parkinson's disease.
    Hirsch EC, Faucheux BA.
    Mov Disord; 1998 Mar; 13 Suppl 1():39-45. PubMed ID: 9613717
    [Abstract] [Full Text] [Related]

  • 15. [The origin of Parkinson's disease].
    Rinne J.
    Duodecim; 1997 Mar; 113(18):1819-24. PubMed ID: 10892075
    [No Abstract] [Full Text] [Related]

  • 16. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
    Geng DY, Li YX, Zee CS.
    Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
    [Abstract] [Full Text] [Related]

  • 17. Circuits and circuit disorders of the basal ganglia.
    DeLong MR, Wichmann T.
    Arch Neurol; 2007 Jan; 64(1):20-4. PubMed ID: 17210805
    [Abstract] [Full Text] [Related]

  • 18. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study.
    Good PF, Olanow CW, Perl DP.
    Brain Res; 1992 Oct 16; 593(2):343-6. PubMed ID: 1450944
    [Abstract] [Full Text] [Related]

  • 19. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease.
    Schocke MF, Seppi K, Esterhammer R, Kremser C, Mair KJ, Czermak BV, Jaschke W, Poewe W, Wenning GK.
    Neuroimage; 2004 Apr 16; 21(4):1443-51. PubMed ID: 15050569
    [Abstract] [Full Text] [Related]

  • 20. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B, Dluzen DE.
    Clin Exp Pharmacol Physiol; 2007 Jul 16; 34(7):555-65. PubMed ID: 17581209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.